Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: December 6, 2007
Last updated: October 21, 2009
Last verified: October 2009

To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6

Condition Intervention Phase
Low Back Pain
Drug: celecoxib
Drug: tramadol HCL
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Six Week Double-Blind, Randomized, Multicenter Comparison Study Of The Analgesic Effectiveness Of Celecoxib 200 Mg BID Compared To Tramadol Hydrochloride 50 Mg QID In Subjects With Chronic Low Back Pain

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Treatment Responders Based on the Numerical Rating Scale-Pain (NRS-Pain) [ Time Frame: Week 6 or Early Termination (ET) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change From Baseline in Severity of Chronic Low Back Pain as Measured by NRS-Pain [ Time Frame: Baseline, Week 6/ET ] [ Designated as safety issue: No ]
  • Change From Baseline in Severity of Low Back Pain as Measured by Visual Analogue Scale (VAS) [ Time Frame: Baseline, Week 6/ET ] [ Designated as safety issue: No ]
  • Patient's Global Assessment of Disease Activity [ Time Frame: Week 6/ET ] [ Designated as safety issue: No ]
  • Physician's Global Assessment of Disease Activity [ Time Frame: Week 6/ET ] [ Designated as safety issue: No ]
  • Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score [ Time Frame: Baseline, Week 6/ET ] [ Designated as safety issue: No ]
  • Change From Baseline in Modified Brief Pain Inventory (m-BPI-sf) [ Time Frame: Baseline, Week 6/ET ] [ Designated as safety issue: No ]
  • Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale [ Time Frame: Baseline, Week 6/ET ] [ Designated as safety issue: No ]
  • Number of Subjects With Change From Baseline in MOS Optimal Sleep Scale Scores [ Time Frame: Baseline, Week 6/ET ] [ Designated as safety issue: No ]
  • Change From Baseline in Work Limitations Questionnaire (WLQ) [ Time Frame: Baseline, Week 6/ET ] [ Designated as safety issue: No ]
  • Patient's Global Evaluation of Study Medication [ Time Frame: Weeks 1, 3, and 6/ET ] [ Designated as safety issue: No ]
  • Patient's Satisfaction Questionnaire (With Pain Relief Scale) [ Time Frame: Week 6/ET ] [ Designated as safety issue: No ]
  • Patient's Satisfaction Questionnaire (With Walking and Bending Ability Scale) [ Time Frame: Week 6/ET ] [ Designated as safety issue: No ]
  • Chronic Low Back Pain Responders Based on VAS, Patient's Global, and RMDQ [ Time Frame: Week 6/ET ] [ Designated as safety issue: No ]

Enrollment: 802
Study Start Date: January 2008
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: celecoxib Drug: celecoxib
200 mg capsules BID for 6 weeks
Active Comparator: tramadol Drug: tramadol HCL
50 mg capsules QID for 6 weeks


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject presents with duration of chronic low back pain of > 3 months requiring regular use of analgesics (> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used

Exclusion Criteria:

  • The subject has chronic low back pain, which is neurologic in etiology (i.e., radiculopathy, neuropathy, myelopathy)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00662558

  Hide Study Locations
United States, Alabama
Pfizer Investigational Site
Birmingham, Alabama, United States, 35242
Pfizer Investigational Site
Birmingham, Alabama, United States, 35126
Pfizer Investigational Site
Birmingham, Alabama, United States, 35235
United States, Arizona
Pfizer Investigational Site
Phoenix, Arizona, United States, 85023
United States, Arkansas
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
United States, California
Pfizer Investigational Site
Anaheim, California, United States, 92801
Pfizer Investigational Site
Long Beach, California, United States, 90806
Pfizer Investigational Site
Oceanside, California, United States, 92056
Pfizer Investigational Site
Sacramento, California, United States, 95825
Pfizer Investigational Site
Sacramento, California, United States, 95823
Pfizer Investigational Site
Wildomar, California, United States, 92595
United States, Colorado
Pfizer Investigational Site
Boulder, Colorado, United States, 80304
Pfizer Investigational Site
Colorado Springs, Colorado, United States, 80904
Pfizer Investigational Site
Denver, Colorado, United States, 80220
United States, Connecticut
Pfizer Investigational Site
Cos Cob, Connecticut, United States, 06807
United States, Florida
Pfizer Investigational Site
Jacksonville, Florida, United States, 32216
Pfizer Investigational Site
Jacksonville, Florida, United States, 32257
Pfizer Investigational Site
Pinellas Park, Florida, United States, 33781
Pfizer Investigational Site
West Palm Beach, Florida, United States, 33409
United States, Georgia
Pfizer Investigational Site
Woodstock, Georgia, United States, 30189
United States, Kansas
Pfizer Investigational Site
Wichita, Kansas, United States, 67214
Pfizer Investigational Site
Wichita, Kansas, United States, 67206
United States, Louisiana
Pfizer Investigational Site
Baton Rouge, Louisiana, United States, 70809
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States, 21218
Pfizer Investigational Site
Columbia, Maryland, United States, 21045
Pfizer Investigational Site
Rockville, Maryland, United States, 20852
Pfizer Investigational Site
Wheaton, Maryland, United States, 20902
United States, Minnesota
Pfizer Investigational Site
St. Paul, Minnesota, United States, 55108
United States, Mississippi
Pfizer Investigational Site
Jackson, Mississippi, United States, 39202
United States, Missouri
Pfizer Investigational Site
Springfield, Missouri, United States, 65807
Pfizer Investigational Site
St. Louis, Missouri, United States, 63141
United States, Nebraska
Pfizer Investigational Site
Omaha, Nebraska, United States, 68134
United States, New York
Pfizer Investigational Site
New Windsor, New York, United States, 12553
Pfizer Investigational Site
New York, New York, United States, 10022-1009
Pfizer Investigational Site
Rochester, New York, United States, 14618
Pfizer Investigational Site
Williamsville, New York, United States, 14221
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97219
United States, Pennsylvania
Pfizer Investigational Site
Bridgeville, Pennsylvania, United States, 15017
Pfizer Investigational Site
Camp Hill, Pennsylvania, United States, 17011
United States, South Carolina
Pfizer Investigational Site
Columbia, South Carolina, United States, 29204
Pfizer Investigational Site
North Charleston, South Carolina, United States, 29406
United States, Tennessee
Pfizer Investigational Site
Bristol, Tennessee, United States, 37620
Pfizer Investigational Site
Collierville, Tennessee, United States, 38017
Pfizer Investigational Site
Johnson City, Tennessee, United States, 37601
Pfizer Investigational Site
Kingsport, Tennessee, United States, 37660
Pfizer Investigational Site
New Tazewell, Tennessee, United States, 37825
United States, Texas
Pfizer Investigational Site
Austin, Texas, United States, 78705
Pfizer Investigational Site
Beaumont, Texas, United States, 77701
Pfizer Investigational Site
Beaumont, Texas, United States, 77706
Pfizer Investigational Site
Dallas, Texas, United States, 75240
Pfizer Investigational Site
Dallas, Texas, United States, 75230
Pfizer Investigational Site
Grapevine, Texas, United States, 76051
Pfizer Investigational Site
Houston, Texas, United States, 77074
Pfizer Investigational Site
Lake Jackson, Texas, United States, 77566
Pfizer Investigational Site
San Angelo, Texas, United States, 76904
Pfizer Investigational Site
San Antonio, Texas, United States, 78217
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84107
United States, Virginia
Pfizer Investigational Site
Richmond, Virginia, United States, 23294
Pfizer Investigational Site
Weber City, Virginia, United States, 24290
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc Identifier: NCT00662558     History of Changes
Other Study ID Numbers: A3191338
Study First Received: December 6, 2007
Results First Received: September 10, 2009
Last Updated: October 21, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Chronic low back pain

Additional relevant MeSH terms:
Back Pain
Low Back Pain
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Analgesics, Non-Narcotic
Analgesics, Opioid
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Central Nervous System Depressants
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on February 27, 2015